Price
$0.7
Increased by +0.16%
Dollar Volume
251.54 K
ADR%
6.57
Earnings Report Date (estimate)
Mar 27, 23 (-0.36)
Market Cap.
69.81 M
Shares Float
85.39 M
Shares Outstanding
99.73 M
Beta
0.75
Price / Earnings
-0.44
BPR
13.04
20D Range
0.62 0.72
50D Range
0.53 0.75
200D Range
0.53 1.82
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.40
Decreased by -2.56%
-0.34
Decreased by -17.65%
Aug 11, 22 -0.44
Increased by +2.22%
-0.34
Decreased by -29.41%
May 12, 22 -0.38
Decreased by -31.03%
-0.31
Decreased by -22.58%
Mar 29, 22 -0.35
Increased by +10.26%
-0.34
Decreased by -2.94%
Nov 4, 21 -0.39
Decreased by -25.81%
-0.37
Decreased by -5.41%
Aug 5, 21 -0.45
Decreased by -25.00%
-0.39
Decreased by -15.38%
May 6, 21 -0.29
Increased by +6.45%
-0.38
Increased by +23.68%
Mar 1, 21 -0.39
Decreased by -34.48%
-0.32
Decreased by -21.88%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-40.13 M
Decreased by -4.61%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-43.76 M
Increased by +1.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-37.91 M
Decreased by -33.31%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-34.41 M
Increased by +8.56%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-38.36 M
Decreased by -38.15%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-44.33 M
Decreased by -51.83%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 7.50 M
Increased by +N/A%
-28.44 M
Decreased by -24.14%
Decreased by -379.15%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-37.63 M
Decreased by -98.85%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.